Why the study?
Do ACE inhibitors reduce proteinuria and slow the progression of renal disease in patients with diabetic and non-diabetic renal failure compared to other antihypertensive drugs?
Do ACE inhibitors reduce proteinuria and slow the progression of renal disease in patients with diabetic and non-diabetic renal failure compared to other antihypertensive drugs?
ACE inhibitors are the treatment of choice for nephroprotection in both diabetic and non-diabetic chronic renal failure, even in normotensive patients.
Answers are grounded in this paper and cite their sources.
May support ACE inhibitor preference for nephroprotection beyond BP control; leaves open confirmatory RCTs in normotensive patients.
Experimental studies have provided evidence that activation of the renin-angiotensin system plays a crucial role in the development and progression of glomerulosclerosis, i.e., the structural equivalent of progressive renal failure. Results of studies in animals, and later in patients with renal failure, documented that angiotensin converting enzyme (ACE) inhibitors exert a specific nephroprotective action: they decrease proteinuria and slow progression more than can be explained solely by their effect on blood pressure. These effects are observed even at doses that do not cause a decrease in systemic blood pressure. Recent controlled studies have shown that ACE inhibitors attenuate proteinuria and progression of renal disease in diabetic and non-diabetic renal disease to a greater extent than other antihypertensive drugs. Thus, ACE inhibitors should be regarded as the treatment of choice in diabetic nephropathy and chronic renal failure of non-diabetic origin, even for normotensive patients.
No takes yet. Share an insight, caveat, or question.
Franek et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: